Prostate Cancer

Prostate cancer is a type of cancer that develops into male reproductive system. Prostate cancer begins when normal cells in the prostate gland start multiplying uncontrollably. It is more prevalent in geriatric men over the age of 65 years. Risk factors for development of prostate cancer are family history, race, and old age. It can be treated by radiation therapy, surgery, chemotherapy, biological therapy, and hormone therapy. The treatment for prostate cancer can be decided on the basis of the stage of cancer. The healthcare professionals such as radiation oncologists and urologists treat prostate cancer. The global prostate cancer treatment market size was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026. Download Free Report Sample @ https://ift.tt/37hUVcV The prostate cancer treatment market is expected to experience significant growth during the forecast period, owing to rise in prevalence of pro...

DNA strand and Cancer Cell Prostate cancer cells with a deletion of the SUCLA2 gene are linked to treatment resistance and metastasis but can be therapeutically targeted with the compound thymoquinone (TQ), according to a study published in Oncogene . Hormone therapy is a standard treatment for metastatic prostate cancer. Almost half of patients develop resistance to this treatment after two years. Previous studies suggest that a mutation in tumor suppressor gene RB1 is a strong driver of treatment resistance and predicts prognosis in patients. Researchers at Kanazawa University in Japan conducted an analysis of prostate cancer cells and found that cells with a RB1 deletion were also missing SUCLA2, a neighboring gene. After examining prostate cancer tissue, the team found that 11% of cases of advanced disease showed both RB1 and SUCLA2 deletion. Upon further analysis, they discovered that the frequency of SUCLA2 loss significantly aligned with RB1 loss at every disease st...

African American and white men with prostate cancer live equally as long if the same care delivery system treats them. (Photo: iStockphoto / NNPA) NNPA NEWSWIRE — @StacyBrownMedia – By Stacy M. Brown, NNPA Newswire Senior National Correspondent -Black men remain more likely to develop more aggressive types of prostate cancer as prostate cancer death rates in African Americans are more than double those of every other racial and ethnic group in the U.S. At a risk rate of 74 percent higher among African American men than non-Hispanic white men, prostate cancer has exacted a deadlier toll on Black men than it does white and all other men of c olor in the United States. According to medical researchers, Black men have the highest risk of developing this cancer and dying from prostate cancer, the most common disease in men and the second-leading cause of cancer-related death in men after lung cancer. Black men remain more likely to develop more aggressive types of prostate cancer as ...

On this page: BasicsTreatment DecisionsActive SurveillanceSurgeryRadiationHormone TherapyChemotherapyTargeted Therapy You’ve just been told you have prostate cancer. Or, maybe someone you love has. That’s frightening, and no doubt you’ll want to know what’s coming next. The good news? We’re here for you, ready to explain your many treatment options—because there are plenty of them, including surgery, radiation, chemotherapy, hormone therapy, immunotherapy, and more. And if you need an extra dash of hope right now, know that most men—we’re talking a solid 98%—live at least 10 years following a diagnosis of this disease. In fact, some men never need any treatment at all. Keep reading. We’ll tell you all we know. First, What Is Prostate Cancer, Again? Your prostate is located in front of your rectum and below your bladder. This one-ounce, walnut-shaped gland helps produce semen, that milky fluid that carries sperm through and then out of your penis when you ejaculate. It gets some ...

DNA strand and Cancer Cell Prostate cancer cells with a deletion of the SUCLA2 gene are linked to treatment resistance and metastasis but can be therapeutically targeted with the compound thymoquinone (TQ), according to a new study published in Oncogene . Hormone therapy is a standard treatment for metastatic prostate cancer. Almost half of patients develop resistance to this treatment after two years. Previous studies suggest that a mutation in tumor suppressor gene RB1 is a strong driver of treatment resistance and predicts prognosis in patients. Researchers at Kanazawa University in Japan conducted an analysis of prostate cancer cells and found that cells with a RB1 deletion were also missing SUCLA2, a neighboring gene. After examining prostate cancer tissue, the team found that 11% of cases of advanced disease showed both RB1 and SUCLA2 deletion. Upon further analysis, they discovered that the frequency of SUCLA2 loss significantly aligned with RB1 loss at every disease st...

Primary care provider's (PCP) role in cancer care is expanding and may include supporting patients in their treatment decisions. However, the degree to which PCPs engage in this role for low-risk prostate cancer is unknown. Characterize PCP perceptions regarding their role in low-risk prostate cancer treatment decision-making. Cross-sectional, national survey. For men with low-risk prostate cancer, PCP reports of (1) confidence in treatment decision-making (high vs. low); (2) intended participation in key aspects of active surveillance treatment decision-making (more vs. less). A total of 347 from 741 eligible PCPs responded (adjusted response rate 56%). Half of respondent PCPs (50.3%) reported high confidence about engaging in low-risk prostate cancer treatment decision-making. The odds of PCPs reporting high confidence were greater among those in solo practice (vs working with > 1 PCP) (OR 2.18; 95% CI 1.14-4.17) and with higher volume of prostate cancer patients (> 15 ...

Men of low socioeconomic status (SES) are more likely to present with metastases when they are diagnosed with prostate cancer (PCa) and are at higher risk for having advanced or aggressive PCa discovered at the time of radical prostatectomy (RP), according to recent studies. 1,2 In addition, men of lower SES are less likely to undergo RP or external beam radiation therapy (EBRT) for localized PCa, and they have decreased cancer-specific survival after these treatments compared with men of higher SES. 3 The reasons are unclear, but urologists in American cities with large poverty-stricken populations say impoverished men with PCa frequently encounter barriers to optimal care, such as poor fundamental health knowledge, no or inadequate health insurance, lack of social support, difficulties with arranging transportation to and from medical appointments, and unstable living situations. The consequences of these impediments include low rates of PCa screening and frequently missed medica...

Exercise Might Help Patients with Prostate Cancer Who are About to Start Treatment Adding positron emission tomography (PET) molecular imaging to conventional cancer screening guided treatment decisions that led to improved disease-free survival (DFS) among men with recurrent prostate cancer, according to findings presented at the virtual American Society for Radiation Oncology 2020 Annual Meeting. The phase II/III EMPIRE-1 (Emory Molecular Prostate Imaging for Radiotherapy Enhancement) trial, enrolled 165 patients with recurrent prostate cancer following prostatectomy. Participants were randomized to either radiation therapy based on conventional screening or treatment based on imaging with the fluciclovine PET radiotracer, a molecular imaging agent. The primary endpoint was failure rate at three years. The main goal of the investigation was to use the advanced molecular imaging to improve post-prostatectomy decision making regarding whether to deliver radiotherapy and optimiz...

For many men, treatment for prostate cancer can result in certain side effects that can greatly impact a patient’s quality of life. However, as Dr. Christopher E. Wolter explains, there are implantable devices that effectively help patients live with those side effects. During the recent virtual CURE ® Educated Patient® Summit on Prostate Cancer, Wolter, a urologist at Mayo Clinic in Arizona, discussed some common side effects that occur in men follow prostate cancer treatment. Wolter also highlighted how effective certain implantable devices are in in treating these common side effects, compared to other available treatments. Approximately 30-70% of men, according to Wolter, experience erectile dysfunction with incontinence of some form following prostate cancer surgery. Similarly, Wolter noted that up to half of patients treated with radiation therapy experience erectile dysfunction with incontinence. The problem, as Wolter noted, is these side effects not only lead to physical d...

In addition to an in-depth look at the role surgery plays in the treatment of prostate cancer, Dr. Mark Tyson, II, an associate professor of urology at the Mayo Clinic in Phoenix, Arizona, recently offered patients a glimpse into the future with an overview of up and coming procedures like focal therapy at CURE® ’s Educated Patient® Prostate Cancer Summit. Basics of Radical Prostatectomy Radical prostatectomy, or the complete removal of the prostate gland, surrounding tissues and seminal vesicles, is the main type of surgical treatment for prostate cancer in men whose disease is located solely in the prostate. As Tyson explained, there are two ways to approach this procedure: robotic, which is how the vast majority of prostatectomies are done today in the United States, or open, which is a more traditional approach that involves a single long incision done by a surgeon. Patients undergoing robotic surgery generally spend one night in the hospital, but Tyson noted that recovery tim...

  PLYMOUTH MEETING, Pa. , Oct. 7, 2020 /PRNewswire/ -- New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low. ADT is considered a cornerstone of treatment for high-risk or advanced prostate cancer and is used in nearly half of all prostate cancer patients. However, it can result in preventable side effects like osteoporosis and bone fractures. Despite clinical recommendations that call for BMD testing in ADT recipients, only 23.4% of the patients studied received testing in 2015. That is up from just 4.1% in 2000. "Although we expected BMD testing rates to be fairly low given the prior literature, we were somewhat surprised that they didn't go up more in recent years," said senior author Alice Dragomir , MSc, PhD, McGill University in Montreal...

PLYMOUTH MEETING, Pa. , Oct. 7, 2020 /PRNewswire/ -- New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low. ADT is considered a cornerstone of treatment for high-risk or advanced prostate cancer and is used in nearly half of all prostate cancer patients. However, it can result in preventable side effects like osteoporosis and bone fractures. Despite clinical recommendations that call for BMD testing in ADT recipients, only 23.4% of the patients studied received testing in 2015. That is up from just 4.1% in 2000. "Although we expected BMD testing rates to be fairly low given the prior literature, we were somewhat surprised that they didn't go up more in recent years," said senior author Alice Dragomir , MSc, PhD, McGill University in Montreal, Qu...

JNCCN October 2020 Cover Credit: NCCN New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low. ADT is considered a cornerstone of treatment for high-risk or advanced prostate cancer and is used in nearly half of all prostate cancer patients. However, it can result in preventable side effects like osteoporosis and bone fractures. Despite clinical recommendations that call for BMD testing in ADT recipients, only 23.4% of the patients studied received testing in 2015. That is up from just 4.1% in 2000. "Although we expected BMD testing rates to be fairly low given the prior literature, we were somewhat surprised that they didn't go up more in recent years," said senior author Alice Dragomir, MSc, Ph.D., McGill University in Montreal, Quebec who work...

HPV vaccine reduces cervical cancer risk   Long-awaited study results from Sweden released this week show for the first time, the impact of the vaccine on cervical cancer. R ates of cervical cancer were 88% lower in women vaccinated before the age of 17 with the HPV vaccine – and 63 % lower in the vaccinated cohort overall . Our news report has more . HPV vaccination has been shown previously to prevent infection with the virus and the development of precancer. Although scientists were confident that it would follow that HPV vaccination would prevent cervical cancer, this is the first time that that has been shown directly. – Professor Peter Sasieni, a Cancer Research UK-funded cervical screening expert at King’s College London   Promising prostate cancer treatment results   A leading cancer charity ha s “hailed a breakthrough” in treating prostate cancer , after results from 2 drug trials were announced at a conference . O laparib improve...